We identified a dual hallmark of MLH1-deficient colorectal cancer- “metabolic suppression-immune activation”-that expands the mechanistic understanding of mismatch repair deficiency and provides a rationale for exploring combined therapeutic strategies targeting mitochondrial metabolic vulnerabilities and immune checkpoint pathways. The gene discussed is MLH1; the disease is colorectal cancer.